These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30930890)

  • 1. A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.
    Wilson KL; Pouniotis D; Hanley J; Xiang SD; Ma C; Coppel RL; Plebanski M
    Front Immunol; 2019; 10():331. PubMed ID: 30930890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.
    Bracho G; Zayas C; Wang L; Coppel R; Pérez O; Petrovsky N
    Malar J; 2009 Feb; 8():35. PubMed ID: 19250541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
    Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
    Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
    Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
    Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
    Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
    Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
    J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
    Burns JM; Flaherty PR; Nanavati P; Weidanz WP
    Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
    Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
    Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.
    Chawla B; Mahajan B; Oakley M; Majam VF; Belmonte A; Sedegah M; Shimp RL; Kaslow DC; Kumar S
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
    Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
    Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.